

**MEDICAL PHARMACY PRIOR AUTHORIZATION REQUEST FORM**  
**TEPEZZA™**

**For authorization, please answer each question and fax this form PLUS chart notes back to the U of U Health Plans Prior Authorization Department at 801-213-1547. Failure to submit clinical documentation to support this request will result in delay and/or denial of the request.**

If you have prior authorization questions, please call for assistance: Healthy U: 855-856-5694, University of Utah Health Employees: 855-856-5690, Individual & Family Plans: 855-869-4769, Commercial Groups: 855-859-4892, MHC: 855-885-7695, Advantage U Part B: 888-605-0858

Date:	Member Name:	ID#:
DOB:	Gender:	Physician:
Office Phone:	Office Fax:	Office Contact:
Height/Weight:	HCPCS Code:	

**Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.**

**Product being requested:**  Tepezza™ (teprotumumab-trbw)

Dosing/Frequency: \_\_\_\_\_

**If the request is for reauthorization, proceed to reauthorization section.**

Questions	Yes	No	Comments/Notes
1. Is the member 18 years of age or older?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Is the prescriber an ophthalmologist?	<input type="checkbox"/>	<input type="checkbox"/>	
3. Does the member have a diagnosis of Graves' disease?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
4. Does the member have a diagnosis of active Thyroid Eye Disease with clinical complications?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
5. Did ocular symptoms begin within 9 months of the baseline assessment?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
6. Is the member's condition moderate to severe as evidenced by one or more of the following: <ul style="list-style-type: none"> <li>• Lid retraction &gt; 2 mm</li> <li>• Moderate to severe soft-tissue involvement</li> <li>• Proptosis ≥ 3 mm above the normal value for race and sex</li> <li>• Periodic or constant diplopia</li> </ul>	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
7. Is the member euthyroid?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
8. Does the provider attest that smoking cessation has been addressed with the member?	<input type="checkbox"/>	<input type="checkbox"/>	
9. Has the member had a 1-month trial and failure or contraindication/intolerance to systemic corticosteroids at the maximum tolerated dose?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>

**Confidentiality Notice**

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.

10. For members with reproductive potential: Does the provider attest the member is not pregnant and has been informed that appropriate forms of contraception should be implemented prior to initiation, during treatment and for 6 months following the last dose of Tepezza™?	<input type="checkbox"/>	<input type="checkbox"/>	
<b>What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.</b>			
Additional information:			
Physician Signature:			

**\*\*Failure to submit clinical documentation to support this request will result in delay and/or denial of the request\*\***

Policy PHARM-M016  
 Origination Date: 03/02/2020  
 Reviewed/Revised Date: 03/25/2020  
 Next Review Date: 03/25/2021  
 Current Effective Date: 03/25/2020

**Confidentiality Notice**

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.